ACRSHealthcare · BiotechnologyThe 12 Wall Street analysts covering Aclaris Therapeutics, Inc. hold a median 12-month price target of $10 — +171.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 3 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Aclaris Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (88): The shares have been drifting up relative to others.
Issuance (40): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ACRS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +171.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Oct 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 Oct 2026 | Canaccord Genuity | Maintains | Buy | $10 → $13 |
| 28 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $16 |
| 28 Oct 2026 | Wedbush | Maintains | Outperform | $10 → $8.00 |
| 1 Sept 2026 | Canaccord Genuity | Initiates | Buy | $10 |
| 1 Sept 2026 | Canaccord Genuity | Initiates | Buy | — |
| 2 June 2026 | LifeSci Capital | Initiates | Outperform | — |
| 5 May 2026 | Guggenheim | Initiates | Buy | — |
| 5 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 29 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 16 Apr 2026 | Oppenheimer | Initiates | Outperform | — |
| 31 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 19 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 July 2025 | Piper Sandler | Assumes | Overweight | $6.00 |
| 25 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 May 2025 | Wedbush | Initiates | Outperform | — |
| 14 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ACRS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Aclaris Therapeutics, Inc. returned +55.9% against +12.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 4% of US stocks
Cheaper than 22% of US stocks
Cheaper than 81% of US stocks
Higher than 17% of US stocks
Higher than 28% of US stocks
Higher than 10% of US stocks
Higher than 5% of US stocks
Higher than 64% of US stocks
Higher than 19% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aclaris Therapeutics, Inc. has a market value of $579.6M and an enterprise value of $460.8M.
Revenue in the twelve months to 30 June 2026: $8.2M. The latest quarter shrank 8.3% year on year.
Net income over the same four quarters: −$75.7M, a −921.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.58.
Free cash flow in the twelve months to 30 June 2026: −$62.2M.
Trailing P/E: −7.0×; forward P/E: −5.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Aclaris Therapeutics, Inc. employs 69 people — $119K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aclaris Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aclaris Therapeutics reported Phase 1b proof-of-concept results for ATI-052 in small studies of atopic dermatitis and asthma. The company said the bispecific antibody was well tolerated and showed early clinical and biomarker signals in both indications.
Why it matters — ACRS watchers may note early findings for a drug candidate being studied in two indications.
Seeking Alpha published a transcript about Aclaris Therapeutics discussing ATI-052 proof-of-concept results in atopic dermatitis and asthma.
Why it matters — The transcript covers proof-of-concept results for ATI-052 in two conditions relevant to Aclaris Therapeutics.
Aclaris priced an underwritten offering of 7,785,714 common shares at $3.50 per share and pre-funded warrants to purchase 6,500,000 shares at $3.49999 each. The securities are all being sold by the company.
Why it matters — ACRS watchers may note the offering’s size and its mix of common shares and pre-funded warrants.
Aclaris Therapeutics announced positive Phase 1b proof-of-concept primary analysis results for ATI-052, its anti-TSLP/IL-4Rα bispecific, in atopic dermatitis. The headline also references asthma.
Why it matters — The results update ACRS watchers on the clinical development of ATI-052.
The item compares Aclaris Therapeutics (ACRS) and Glaukos (GKOS) with their sector based on performance so far this year; the excerpt provides no results.
Why it matters — ACRS watchers may find the sector comparison relevant, but the excerpt does not say whether ACRS outperformed or lagged.
The 12 Wall Street analysts covering Aclaris Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $4 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Aclaris Therapeutics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aclaris Therapeutics, Inc. 74 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Aclaris Therapeutics, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +171.7% from the last close, and Ticker Nerd's factor model ranks Aclaris Therapeutics, Inc. 74 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aclaris Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $16 over the next 12 months.
Aclaris Therapeutics, Inc. returned +55.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small- and large-molecule therapies for immuno-inflammatory diseases.
The most recent item we track (MarketBeat, 27 Oct 2026): "Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b". Aclaris Therapeutics reported Phase 1b proof-of-concept results for ATI-052 in small studies of atopic dermatitis and asthma. The company said the bispecific antibody was well tolerated and showed early clinical and biomarker signals in both indications.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small- and large-molecule therapies for immuno-inflammatory diseases. The company centers its work on conditions with significant unmet medical need, using its proprietary KINect drug discovery platform and integrated research capabilities to advance product candidates through early development. Aclaris Therapeutics’ portfolio includes therapeutics aimed at inflammatory and autoimmune disorders, with programs spanning dermatology-related conditions and other immune-mediated diseases. In addition to its core therapeutics business, the company operates a contract research segment through Confluence Discovery Technologies, which provides laboratory and drug discovery services to pharmaceutical and biotechnology partners. Based in Wayne, Pennsylvania, Aclaris Therapeutics plays a specialized role in the biopharmaceutical market by combining internal drug development with research services for external collaborators.
CEO Dr. Neal S. Walker D.O., M.D. · 69 employees · United States · https://www.aclaristx.com
